A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial

被引：0
|
作者：
Collins C. Iwuji
Duncan Churchill
Stephen Bremner
Nicky Perry
Ye To
Debbie Lambert
Chloe Bruce
Laura Waters
Chloe Orkin
Anna Maria Geretti
机构：
[1] University of Sussex,Department of Global Health and Infection, Brighton and Sussex Medical School
[2] Brighton and Sussex University Hospitals NHS Trust,Department of Primary Care and Public Health, Brighton and Sussex Medical School
[3] University of Sussex,Brighton & Sussex Clinical Trials Unit
[4] University of Sussex,undefined
[5] The Mortimer Market Centre,undefined
[6] Central and North West London NHS Foundation Trust,undefined
[7] Barts Health NHS Trust,undefined
[8] Queen Mary University of London,undefined
[9] Institute of Infection,undefined
[10] University of Liverpool,undefined
来源：
BMC Infectious Diseases | / 20卷
关键词：
HIV; Antiretroviral drugs; Drug resistance; Protease inhibitor; B/F/TAF; Integrase inhibitor; Pilot; Phase IV randomised trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 17 条
  • [1] A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naive, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial
    Iwuji, Collins C.
    Churchill, Duncan
    Bremner, Stephen
    Perry, Nicky
    To, Ye
    Lambert, Debbie
    Bruce, Chloe
    Waters, Laura
    Orkin, Chloe
    Geretti, Anna Maria
    [J]. BMC INFECTIOUS DISEASES, 2020, 20 (01)
  • [2] Switching to bictegravir/emtricitabine/tenofovir alafenamide single tablet regimen from boosted protease inhibitor-based ART in virologically suppressed adults with HIV-1 harbouring drug resistance: a phase IV randomised, open-label pilot study (PIBIK study)
    Iwuji, C.
    Waters, L.
    Milinkovic, A.
    Orkin, C.
    Perry, N.
    Dailey, N.
    To, Y.
    Bremner, S.
    Geretti, A.
    Churchill, D.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 89 - 90
  • [3] Switching to bictegravir/ emtricitabine/tenofovir alafenamide single tablet regimen from boosted protease inhibitor-based ART in virologically suppressed adults with HIV-1 harbouring drug resistance - A phase IV randomized, open-label pilot study (PIBIK study)
    Iwuji, C.
    Waters, L.
    Milinkovic, A.
    Orkin, C.
    Fox, J.
    Post, F.
    Perry, N.
    Bruce, C.
    Dailey, N.
    To, Y.
    Bremner, S.
    Geretti, A. M.
    Churchill, D.
    [J]. HIV MEDICINE, 2023, 24 : 681 - 683
  • [4] Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1:48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial
    Daar, Eric S.
    Dejesus, Edwin
    Ruane, Peter
    Crofoot, Gordon
    Oguchi, Godson
    Creticos, Catherine
    Rockstroh, Juergen K.
    Molina, Jean-Michel
    Koenig, Ellen
    Liu, Ya-Pei
    Custodio, Joseph
    Andreatta, Kristen
    Graham, Hiba
    Cheng, Andrew
    Martin, Hal
    Quirk, Erin
    [J]. LANCET HIV, 2018, 5 (07): : E347 - E356
  • [5] Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial
    Maggiolo, Franco
    Rizzardini, Giuliano
    Raffi, Francois
    Pulido, Federico
    Gracia Mateo-Garcia, Maria
    Molina, Jean-Michel
    Ong, Edmund
    Shao, Yongwu
    Piontkowsky, David
    Das, Moupali
    McNicholl, Ian
    Haubrich, Richard
    [J]. LANCET HIV, 2019, 6 (10): : E655 - E666
  • [6] Phase IIIb, randomized, open-label study to evaluate switching from a tenofovir disoproxil fumarate (TDF)-containing regimen to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically suppressed, HIV-1 infected participants aged ≥60
    Maggiolo, F.
    Rizzardini, G.
    Raffi, F.
    Pulido, F.
    Mateo Garcia, G.
    Molina, J.
    Ong, E.
    Shao, Y.
    Corales, R.
    McNicholl, I.
    Piontkowsky, D.
    Das, M.
    Haubrich, R.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [7] SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen
    Campo, R.
    DeJesus, E.
    Bredeek, U. F.
    Henry, K.
    Khanlou, H.
    Logue, K.
    Brinson, C.
    Benson, P.
    Dau, L.
    Wang, H.
    White, K.
    Flaherty, J.
    Fralich, T.
    Guyer, B.
    Piontkowsky, D.
    [J]. CLINICAL INFECTIOUS DISEASES, 2013, 56 (11) : 1637 - 1645
  • [8] Efficacy and safety of switching from boosted protease inhibitor plus emtricitabine/tenofovir disoproxil fumarate regimens to the single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults through 24 weeks: EMERALD study
    Molina, J-M
    Gallant, J.
    Orkin, C.
    Negredo, E.
    Bhatti, L.
    Gathe, J.
    Van Landuyt, E.
    Lathouwers, E.
    Hufkens, V.
    Vanveggel, S.
    Opsomer, M.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20 : 28 - 28
  • [9] A phase 3b open-label pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) single tablet regimen (STR) in virologically suppressed HIV-1 infected adults harbouring the NRTI resistance mutation M184V and/or M184I (GS-US-292-1824)
    Perez-Valero, I.
    Llibre, J. M.
    Pulido, F.
    Molina, J-M
    Esser, S.
    McNicholl, I.
    Lorgeoux, R-P
    Piontkowsky, D.
    Sathia, L.
    Haubrich, R.
    [J]. HIV MEDICINE, 2018, 19 : S21 - S21
  • [10] Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study
    Mills, Anthony
    Arribas, Jose R.
    Andrade-Villanueva, Jaime
    DiPerri, Giovanni
    Van Lunzen, Jan
    Koenig, Ellen
    Elion, Richard
    Cavassini, Matthias
    Madruga, Jose Valdez
    Brunetta, Jason
    Shamblaw, David
    DeJesus, Edwin
    Orkin, Chloe
    Wohl, David A.
    Brar, Indira
    Stephens, Jeffrey L.
    Girard, Pierre-Marie
    Huhn, Gregory
    Plummer, Andrew
    Liu, Ya-Pei
    Cheng, Andrew K.
    McCallister, Scott
    [J]. LANCET INFECTIOUS DISEASES, 2016, 16 (01): : 43 - 52
12